AllSight
Companies · COGT · Pharmaceutical Preparations

Cogent Biosciences, Inc. (COGT)

Cogent Biosciences, Inc. (COGT) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Cogent Biosciences, Inc. (COGT) stock — financials & valuation

Key numbers for Cogent Biosciences, Inc. (COGT): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 31/100 — a percentile rank of Cogent Biosciences, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$5.5B
EV / EBITDA-14.3×
Return on equity-62.4%
ROIC-67.7%
Debt / equity0.4×
Dividend yield0.0%

Is Cogent Biosciences, Inc. overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Cogent Biosciences, Inc.’s own financial statements and shown as context, never as advice.

Sep 2, 2026Five-year supply agreement
Cogent signs five-year bezuclastinib supply deal, but purchase commitments remain opaque
Aug 10, 2026
Launch preparation advances, but the quarter mostly confirms the expected path
Aug 10, 2026
New $400M ATM adds dilution overhang without immediate funding need
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact